Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells
Open Access
- 31 October 2010
- journal article
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 3 (1) , 43
Abstract
Hepatocellular carcinoma (HCC) still is a big burden for China. In recent years, the third-generation platinum compounds have been proposed as potential active agents for HCC. However, more experimental and clinical data are warranted to support the proposal. In the present study, the effect of lobaplatin was assessed in five HCC cell lines and the underlying molecular mechanisms in terms of cell cycle kinetics were explored.Keywords
This publication has 26 references indexed in Scilit:
- Systemic Therapy for Hepatocellular Carcinoma: Cytotoxic Chemotherapy, Targeted Therapy and ImmunotherapyAnnals of Surgical Oncology, 2008
- Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trialBritish Journal of Cancer, 2007
- Repression of cell cycle–related proteins by oxaliplatin but not cisplatin in human colon cancer cellsMolecular Cancer Therapeutics, 2006
- Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL ConferenceJournal of Hepatology, 2001
- Lobaplatin: a new antitumour platinum drugExpert Opinion on Investigational Drugs, 2001
- In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cellsCarcinogenesis, 1996
- Inhibitors of mammalian G1 cyclin-dependent kinases.Genes & Development, 1995
- Phase I Clinical Trial of Lobaplatin (D-19466) after Intravenous Bolus InjectionOncology Research and Treatment, 1994
- CIS‐diamminedichloroplatinum(II) inhibits p34cdc2 protein kinase in human lung‐cancer cellsInternational Journal of Cancer, 1993
- Universal control mechanism regulating onset of M-phaseNature, 1990